January 2026
1. KIM TY, Min GJ, Cho SG, Kim S, et al
   Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.
   PLoS One. 2026;21:e0328666.
   

   >> Share

   
   
2. CHAROENRIT P, Niparuck P, Rotjanapan P
   Real-world clinical effectiveness of trimethoprim-sulfamethoxazole for primary prophylaxis of pneumocystis pneumonia in non-hodgkin lymphoma patients treated with rituximab.
   PLoS One. 2026;21:e0344273.
   

   >> Share

   
   
3. 
   Expression of Concern: Trends and disparities in Non-Hodgkin Lymphoma related mortality in the United States, 1999-2020.
   PLoS One. 2026;21:e0346387.
   

   >> Share

   
   
4. 
   Retraction: A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever.
   PLoS One. 2026;21:e0347091.
   

   >> Share

   
   
5. JIANG W, Liu P
   Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study.
   PLoS One. 2026;21:e0350024.
   

   >> Share

   
   
6. OKOTH SA, Tonui RK, Maina TK, Agwati E, et al
   The impact of malaria-induced neutrophil subset shift and a link to Burkitt lymphoma.
   PLoS One. 2026;21:e0348729.
   

   >> Share

   
   
7. RJOOP A, Al-Samama'h R, Al-Ullemat TS, Alshamali R, et al
   Clinical characteristics and outcomes of Hodgkin Lymphoma: A single institution retrospective cohort study.
   PLoS One. 2026;21:e0353363.
   

   >> Share

   
   
8. 
   Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients.
   PLoS One. 2026;21:e0356789.
   

   >> Share

   
   
9. LUQUE-BENAVIDES R, Cruz Ku G, Valcarcel B, Garcia A, et al
   Primary ocular-adnexal non-Hodgkin Lymphoma in a Peruvian cohort: An 18-year experience.
   PLoS One. 2026;21:e0356381.
   

   >> Share

   
   
10. MARTINEZ ALCALA R, Visser L, Fortpied C, Ferme C, et al
    Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.
    PLoS One. 2026;21:e0360080.
    

    >> Share

    
    January 2025
11. TSUTSUE S, Makita S, Asou H, Wada S, et al
    Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012-2022.
    PLoS One. 2025;20:e0317439.
    

    >> Share

    
    
12. SALAS LC, Mielczarski B, Rivero RC, da Cunha Filho JSL, et al
    BCL6 (B-cell lymphoma 6) expression in adenomyosis, leiomyomas and normal myometrium.
    PLoS One. 2025;20:e0317136.
    

    >> Share

    
    
13. ZHANG H, Dong W, Zhang L, Ma B, et al
    NOTCH1 promotes the elevation of GM-CSF and IL-6 through the EZH2/STAT3 pathway to facilitate the fibrotic state of the myocardium in DLBCL.
    PLoS One. 2025;20:e0316923.
    

    >> Share

    
    
14. LIN R, Tian A, Wang Y, Wang X, et al
    The predictive value of changes in 18F-FDG PET/CT cardiac uptake patterns and metabolic parameters for anthracycline based chemotherapy induced cardiac toxicity in lymphoma patients.
    PLoS One. 2025;20:e0319442.
    

    >> Share

    
    
15. POMARES AA, Merino LR, Gonzalez S, Morata J, et al
    Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma.
    PLoS One. 2025;20:e0318689.
    

    >> Share

    
    
16. UAWITHYA E, Kulchutisin K, Jitprapaikulsan J, Leelakanok N, et al
    Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0319714.
    

    >> Share

    
    
17. WEI S, Sun J, Wen J, Yu J, et al
    High SRD5A3 expression is correlated with promotion of proliferation and inhibition of apoptosis in B-cell non-Hodgkin lymphoma and suggests a poor prognosis.
    PLoS One. 2025;20:e0323965.
    

    >> Share

    
    
18. TAN F, Li Y, Xia H, Yin W, et al
    Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.
    PLoS One. 2025;20:e0322378.
    

    >> Share

    
    
19. TIAN Y, Yang W, Xu J, Li Y, et al
    Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database.
    PLoS One. 2025;20:e0324532.
    

    >> Share

    
    
20. ALANAZI TM
    Enhancing precision in lymphoma detection with novel deep transformer-based neural networks.
    PLoS One. 2025;20:e0329261.
    

    >> Share

    
    
21. XU L, Tu G, Cai Z, Lan T, et al
    Predicting in-hospital mortality in ICU patients with lymphoma using machine learning models.
    PLoS One. 2025;20:e0330197.
    

    >> Share

    
    
22. ERDOGAN MS
    On nonparametric estimating ROC curve based on non-uniform rational B-spline.
    PLoS One. 2025;20:e0330175.
    

    >> Share

    
    
23. THEIL DE, Butow C, Scharf S, Schafer H, et al
    Behavioral investigation of reactive and neoplastic lymphocytes in human lymph nodes in 4D.
    PLoS One. 2025;20:e0331439.
    

    >> Share

    
    
24. VAUGHAN J, Patel M, Lawrie D, Machaba M, et al
    Correction: The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma.
    PLoS One. 2025;20:e0331945.
    

    >> Share

    
    
25. CHEN L, Lu Z, Zhang X, Lai J, et al
    Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients.
    PLoS One. 2025;20:e0332421.
    

    >> Share

    
    
26. SAAD M, Aisha E, Sohail MU, Sajid M, et al
    Trends and disparities in Non-Hodgkin Lymphoma related mortality in the United States, 1999-2020.
    PLoS One. 2025;20:e0327809.
    

    >> Share

    
    
27. ANTONUCCI A, Lucas AR, Costa J, Norton S, et al
    Physical activity is associated with exercise capacity among patients undergoing chemotherapy: A pilot randomized controlled trial.
    PLoS One. 2025;20:e0329774.
    

    >> Share

    
    
28. ZHOU M, Jiang C, Su C
    Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.
    PLoS One. 2025;20:e0336151.
    

    >> Share

    
    
29. NAKAMURA M, Matsumoto Y, Nagata M, Yasuda K, et al
    Exploring DNA methylation profiles in blood samples of canine gastrointestinal lymphoma.
    PLoS One. 2025;20:e0339388.
    

    >> Share

    
    January 2024
30. ANGELILLO C, Tock WL, Salaciak M, Reid RER, et al
    A single-armed proof-of-concept study of Lymfit: A personalized, virtual exercise intervention to improve health outcomes in lymphoma survivors in the pandemic.
    PLoS One. 2024;19:e0275038.
    

    >> Share

    
    
31. SARPA M, da Costa VIDB, Ferreira SN, de Almeida CA, et al
    Investigation of occupational risk factors for the development of non-Hodgkin's lymphoma in adults: A hospital-based case-control study.
    PLoS One. 2024;19:e0297140.
    

    >> Share

    
    
32. YU N, Zhang W, Zhong X, Song X, et al
    Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study.
    PLoS One. 2024;19:e0300330.
    

    >> Share

    
    
33. HESSELING PB, Afungchwi GM, Njodzeka BW, Wharin P, et al
    Burkitt lymphoma: The effect of age, sex and delay to diagnosis on treatment completion and outcome of treatment in 934 Patients in Cameroon.
    PLoS One. 2024;19:e0299777.
    

    >> Share

    
    
34. GORRES KL, Reineke DM, Miller G
    Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein-Barr virus lytic reactivation.
    PLoS One. 2024;19:e0299198.
    

    >> Share

    
    
35. BIJOU I, Liu Y, Lu D, Chen J, et al
    Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
    PLoS One. 2024;19:e0289902.
    

    >> Share

    
    
36. RAINEY NE, Armand AS, Petit PX
    Sodium arsenite and arsenic trioxide differently affect the oxidative stress of lymphoblastoid cells: An intricate crosstalk between mitochondria, autophagy and cell death.
    PLoS One. 2024;19:e0302701.
    

    >> Share

    
    
37. ZHANG Q, Li L, Yang H
    Application of fused graphical lasso to statistical inference for multiple sparse precision matrices.
    PLoS One. 2024;19:e0304264.
    

    >> Share

    
    
38. BATTAH MM, Zainal H, Ibrahim DA, Md Hanafiah NHB, et al
    Evaluation of clinicians' knowledge and practice regarding pharmacotherapy of Non-Hodgkin's lymphoma: A multi-center study in Yemen.
    PLoS One. 2024;19:e0304209.
    

    >> Share

    
    
39. HE L, He W
    Clinicopathologic features and outcomes of bilateral lacrimal gland lesions.
    PLoS One. 2024;19:e0305717.
    

    >> Share

    
    
40. OLAND CB, Ranch LS, Skaaby T, Delvin T, et al
    Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome.
    PLoS One. 2024;19:e0304145.
    

    >> Share

    
    
41. YIMPAK P, Bumroongkit K, Tantiworawit A, Rattanathammethee T, et al
    Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand.
    PLoS One. 2024;19:e0307253.
    

    >> Share

    
    
42. ESLAMI M, Mehrabi M, Payandeh M, Saba F, et al
    Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
    PLoS One. 2024;19:e0308247.
    

    >> Share

    
    
43. CRISI PE, Giordano MV, Luciani A, Gramenzi A, et al
    Evaluation of the fatty acid-based erythrocyte membrane lipidome in cats with food responsive enteropathy, inflammatory bowel disease and low-grade intestinal T-cell lymphoma.
    PLoS One. 2024;19:e0307757.
    

    >> Share

    
    
44. LI Q, Zhang K, Yu Y, Yu Z, et al
    TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma.
    PLoS One. 2024;19:e0310889.
    

    >> Share

    
    
45. DETRAIT MY, Warnon S, Lagasse R, Dumont L, et al
    A machine learning approach in a monocentric cohort for predicting primary refractory disease in Diffuse Large B-cell lymphoma patients.
    PLoS One. 2024;19:e0311261.
    

    >> Share

    
    
46. WANG Q, Huang T, Wei X
    Impact of prior cancer history on the prognosis of extranodal NK/T-cell lymphoma.
    PLoS One. 2024;19:e0311094.
    

    >> Share

    
    
47. LIU K, Yang Q, Liu P, Zhu K, et al
    CD70 is a potential prognostic marker and significantly regulates cellular function in diffuse large B-cell lymphoma.
    PLoS One. 2024;19:e0312445.
    

    >> Share

    
    
48. PANDIYAN A, Lari S, Vanka J, Kumar BS, et al
    Plasma pesticide residues-serum 8-OHdG among farmers/non-farmers diagnosed with lymphoma, leukaemia and breast cancers: A case-control study.
    PLoS One. 2024;19:e0295625.
    

    >> Share

    
    
49. SILVA MA, Williams S, Hauert S, Ovadia B, et al
    Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.
    PLoS One. 2024;19:e0313026.
    

    >> Share

    
    
50. CONTE M, Fournier A, Rothwell JA, Boutron-Ruault MC, et al
    MALTectomy and psoriasis risk in women: A prospective study in the French E3N prospective cohort.
    PLoS One. 2024;19:e0310891.
    

    >> Share

    
    
51. LU S, Zeng L, Mo G, Lei D, et al
    Correction: Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p.
    PLoS One. 2024;19:e0317025.
    

    >> Share

    
    
52. YEH SA, Chiu LC, Lin HC, Li HJ, et al
    Trends in the incidence of the Epstein-Barr virus-associated malignancies extranodal NK/T-cell lymphoma and nasopharyngeal carcinoma in Taiwan.
    PLoS One. 2024;19:e0315380.
    

    >> Share

    
    January 2023
53. 
    Expression of Concern: Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.
    PLoS One. 2023;18:e0292986.
    

    >> Share

    
    
54. LU S, Zeng L, Mo G, Lei D, et al
    Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p.
    PLoS One. 2023;18:e0294729.
    

    >> Share

    
    
55. BOLAND V, Drury A, Brady AM
    Content comparison of unmet needs self-report measures for lymphoma cancer survivors: A systematic review.
    PLoS One. 2023;18:e0290729.
    

    >> Share

    
    
56. SHYU JY, Schlag PA, Karwowska SM, Manohar CF, et al
    Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
    PLoS One. 2023;18:e0292251.
    

    >> Share

    
    
57. SWAIN RM, Sanchez A, Gutierrez DA, Varela-Ramirez A, et al
    Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells.
    PLoS One. 2023;18:e0295441.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share